I would like to thank *PLoS Medicine* for publishing Lacasse and Leo\'s important and methodical Essay that debunks the "chemical imbalance" advertisements for psychiatric drugs \[ [@pmed-0030117-b1]\]. Why would the United States Food and Drug Administration (FDA) approve such ads? Our human rights group, MindFreedom International, has been asking that question for a long time. On behalf of MindFreedom, US Senator Ron Wyden contacted the FDA for an explanation about why they approve such advertising. In their response---which took over one year to receive---the FDA could cite no scientific literature or studies. It turns out there\'s a good reason that the FDA can\'t find any scientific evidence for the claims of a "chemical imbalance" in these ads: the scientific evidence in support of the serotonin hypothesis is very weak.

Readers who would like more information about the psychiatric industry\'s advertising suggesting a "chemical imbalance" in depression may be interested in the following: (1) MindFreedom\'s debate with Pfizer, manufacturer of Zoloft, available at <http://www.mindfreedom.org/mindfreedom/pfizerlies.shtml>, and (2) a historic debate with the American Psychiatric Association resulting from MindFreedom\'s 2003 hunger strike, available at <http://www.mindfreedom.org/mindfreedom/hungerstrike.shtml> (Researcher Jonathan Leo was on the MindFreedom International Scientific Panel for the hunger strike).
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